Association between femoral localized cortical thickening (“beaking” or “flaring”) and bisphosphonate duration in glucocorticoid-induced osteoporosis
- 5 January 2026
- journal article
- research article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 44 (3) , 354-362
Abstract
Introduction Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and bisphosphonates (BPs) are widely used for treatment. Localized cortical thickening (LCT, “beaking” or “flaring”) is a characteristic radiographic finding and a potential precursor of atypical femoral fracture, a known complication of long-term BP use. The incidence of LCT and its association with BP duration in GIOP remain unclear. Materials and methods In this cross-sectional study, 86 outpatients with GIOP (mean age, 60.6 years; 62.8% women) were included. Femoral radiographs were evaluated for LCT, cortical thickness index (CTI; diaphyseal/subtrochanteric), and lateral bowing angle (LBA). Patients were stratified by BP duration (≥2 or ≥4 years), and 1:1 propensity score matching was used to evaluate the association with LCT. Associations of BP duration with CTI and LBA were analyzed using linear mixed-effects models; correlations with bone turnover markers (BTMs) and bone mineral density (BMD) were also examined. Results LCT was observed in 11 (12.8%) patients, including 10 undergoing BP therapy. Patients with LCT had a significantly longer duration of BP use (median: 8.0 years vs. 1.2 years, p <0.01). After matching, BP use for ≥4 years was significantly associated with LCT (odds ratio=11.29, p=0.01), whereas that for ≥2 years was not. Diaphyseal CTI significantly increased with BP duration; no associations were found with subtrochanteric CTI, LBA, BTMs, or BMD. Conclusion In GIOP, prolonged BP use, especially for ≥4 years, was associated with LCT and greater diaphyseal cortical thickness. Radiographic assessment is essential in patients with GIOP and long-term BP use.Keywords
This publication has 46 references indexed in Scilit:
- Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone‐Modifying Agents for Bone Metastases: A Cross‐Sectional StudyJBMR Plus, 2023
- Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019JAMA Network Open, 2021
- Cortical Thickness of the Femur and Long-Term Bisphosphonate UseJournal of Bone and Mineral Research, 2014
- Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2013
- Incidence of atypical nontraumatic diaphyseal fractures of the femurJournal of Bone and Mineral Research, 2012
- Increasing Occurrence of Atypical Femoral Fractures Associated With Bisphosphonate UseArchives of internal medicine (1960), 2012
- Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older WomenJAMA, 2011
- Should bisphosphonates be used for long‐term treatment of glucocorticoid‐induced osteoporosis?Arthritis & Rheumatism, 2010
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral ResearchJournal of Bone and Mineral Research, 2010
- Effects of Continuing or Stopping Alendronate After 5 Years of TreatmentJAMA, 2006